A detailed history of Black Rock Inc. transactions in Co Diagnostics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 502,025 shares of CODX stock, worth $366,478. This represents 0.0% of its overall portfolio holdings.

Number of Shares
502,025
Previous 500,050 0.39%
Holding current value
$366,478
Previous $560,000 11.96%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$1.01 - $1.7 $1,994 - $3,357
1,975 Added 0.39%
502,025 $627,000
Q1 2024

May 10, 2024

SELL
$1.06 - $1.42 $1,886 - $2,527
-1,780 Reduced 0.35%
500,050 $560,000
Q4 2023

Feb 13, 2024

SELL
$1.0 - $1.5 $878 - $1,317
-878 Reduced 0.17%
501,830 $667,000
Q3 2023

Nov 13, 2023

SELL
$1.03 - $1.85 $3,915 - $7,031
-3,801 Reduced 0.75%
502,708 $532,000
Q2 2023

Aug 11, 2023

BUY
$1.04 - $1.64 $5,098 - $8,039
4,902 Added 0.98%
506,509 $562,000
Q1 2023

May 12, 2023

SELL
$1.39 - $3.24 $52,158 - $121,577
-37,524 Reduced 6.96%
501,607 $742,000
Q4 2022

Feb 13, 2023

SELL
$2.32 - $3.68 $1,076 - $1,707
-464 Reduced 0.09%
539,131 $1.36 Million
Q3 2022

Nov 14, 2022

BUY
$2.87 - $7.01 $108,925 - $266,050
37,953 Added 7.57%
539,595 $1.73 Million
Q2 2022

Aug 12, 2022

BUY
$3.76 - $6.29 $53,256 - $89,091
14,164 Added 2.91%
501,642 $2.81 Million
Q1 2022

May 12, 2022

SELL
$5.03 - $9.61 $14,929 - $28,522
-2,968 Reduced 0.61%
487,478 $3.01 Million
Q4 2021

Feb 10, 2022

SELL
$8.12 - $10.37 $331,458 - $423,303
-40,820 Reduced 7.68%
490,446 $4.38 Million
Q3 2021

Nov 09, 2021

BUY
$7.48 - $11.38 $99,693 - $151,672
13,328 Added 2.57%
531,266 $5.17 Million
Q2 2021

Aug 11, 2021

BUY
$7.16 - $9.56 $3.71 Million - $4.95 Million
517,938 New
517,938 $4.27 Million

Others Institutions Holding CODX

About Co-Diagnostics, Inc.


  • Ticker CODX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 33,781,000
  • Market Cap $24.7M
  • Description
  • Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and ...
More about CODX
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.